NCT05827653View on ClinicalTrials.gov

MAD Study of NX210c

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

December 5, 2022

Primary Completion Date

April 29, 2023

Study Completion Date

October 2, 2023

Conditions

Healthy Elderly

Interventions

DRUG

NX210c

3 times a week, for 28 days

DRUG

Placebo

3 times a week, for 28 days

Trial Locations (1)

2333 CL

Centre for Human Drug Research, Leiden

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

Centre for Human Drug Research, Netherlands

OTHER

lead

Axoltis Pharma

INDUSTRY

NCT05827653 - MAD Study of NX210c | Biotech Hunter | Biotech Hunter